Instylla – Developing Next-generation Liquid Embolics
Instylla is a privately held company based in Bedford, MA, focused on developing next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis. The company’s first product, Embrace™ Hydrogel Embolic System, is designed for controlled, complete, and persistent embolization in these clinical conditions.
Instylla was founded in 2017 by Incept LLC and is funded by several leading venture capital groups.
Restoring life, hope, and joy to the world’s sickest patients by materializing novel embolization solutions to improve outcomes.
Amarpreet Sawhney, Ph.D., is the Founder, Chief Executive Officer and Chairman of the Board of Directors. He is also the CEO of Pramand LLC, and Rejoni, Inc. Prior to this Dr. Sawhney served as CEO and Chairman of Augmenix (acquired by Boston Scientific) and Ocular Therapeutix (NASDAQ: OCUL) . In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of AccessClosure, Inc., acquired by Cardinal Health. Dr. Sawhney’s innovations are the subject of over 120 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.
Pat Campbell has over 20 years with the Incept family of companies. He was the President and CTO of Augmenix, which was sold to Boston Scientific in 2018. Before that Pat was the VP of Research and Development at Confluent Surgical, which was sold to Tyco Healthcare in 2006. Previously Pat worked at Focal, Inc., Advanced Cardiovascular Systems, and Symbion, Inc. Pat holds a PhD and Masters in Bioengineering, and a BS in Mechanical Engineering from the University of Utah. Pat also has over 20 issued U.S. patents.
Ray Lareau has over 20 years of experience in research, development, commercialization, and manufacturing of medical devices in array of fields including interventional radiology, endoscopy, urology, oncology, and cardiology. His previous positions were at Angiodynamics, Navilyst, Boston Scientific, and Hitachi where he was responsible for the development and commercialization of an array of medical devices. His efforts have resulted in over 30 issued and pending patents inclusive of implantable and catheter technologies. Ray holds a B.S. and M.S. in Plastics Engineering.
VP of Quality and Regulatory
Amita Shah has over 28 years of experience in regulatory and quality for cardiovascular, neurological and implantable medical devices. She has worked for ConforMIS, Confluent Surgical, Hemasure, and CR Bard Vascular/Cardiology where she authored and successfully cleared more than 25 510ks and participated in the PMA approval process. Amita has a M.S. in Chemistry.
VP of R&D and operations
Ben Bell has over 20 years of experience in product design, development, commercialization, and manufacturing of medical devices. He has worked for Boston Scientific, Navilyst Medical, Angiodynamics, and Hitachi where he was responsible for the development and commercialization of medical devices in fields including Vascular Access, Peripheral Vascular, Endoscopy, and Cardiology. Ben holds a B.S. in Plastics Engineering. He also has over 20 issued and pending patents.
Sr. Director of Business Operations
Janet has over 25 years of experience in a broad range of operational roles, including procurement, HR, accounting, and facilities build out and management at early-stage life science and technology companies and venture capital firms. She has held previous positions held at Focal Inc, Charles River Ventures, Reva Systems, mValent, Prism Venture Partners, FirstFuel Software and Coretelligent.